Cases & Deals

  • Home
  • Practices
  • Invus participates in €20 million investment in Sensorion

Share

Invus participates in €20 million investment in Sensorion

June 2019

Client(s) Invus

Jones Day advised Invus, as lead investor, alongside with Sofinnova, in the €20 million (US$22.6 million) convertible bonds issue of Sensorion, a clinical-stage biopharmaceutical company, which specializes in the development of novel therapies to restore, treat, and prevent inner ear diseases.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.